Biomatter Raises $18M for AI Enzymes

Lithuanian biotech Biomatter raised $18 million in an oversubscribed Series A round led by Astanor. CEO Laurynas Karpus leads the company, which plans to open a 2,000-square-metre facility in Vilnius in 2027. The funding supports US expansion and a larger commercial team to reduce enzyme development cycles from weeks to days.